[Treatment of obstructive disease with fenoterol-ipratropiumbromid dosage aerosol (IK 6). Short and long-terms results (author's transl)].
Fenoterol-Ipratropiumbromid dosage aerosol (IK 6) showed in acute experiments on patients with chronic obstructive disease optimal bronchodilatation. In this mixture of Fenoterol and Ipratropiumbromid only 50% of the optimal dosage of the beta 2-stimulator is present. This minimizes the side-effects and increases the therapeutic range. Still the bronchodilatation is optimal. 92 patients were treated with this mixture for between 1 and 160 months. No side-effects were seen. The optimal bronchodilatatoric effect was always present.
D000336:Aerosols; D001249:Asthma / Q000188:drug therapy*; D001286:Atropine Derivatives / Q000627:therapeutic use*; D004338:Drug Combinations; D004357:Drug Synergism; D004983:Ethanolamines / Q000627:therapeutic use*; D005280:Fenoterol / Q000627:therapeutic use*; D006801:Humans; D009241:Ipratropium / Q000627:therapeutic use*
D000336:Aerosols; D001286:Atropine Derivatives; D004338:Drug Combinations; D004983:Ethanolamines; D005280:Fenoterol; D009241:Ipratropium
Die Behandlung obstruktiver Atemwegserkrankungen mit Fenoterol-Ipratropiumbromidgemisch-Dosieraerosol (IK 6).